Johnson & Johnson (JNJ) is one of the largest healthcare companies in the world. It employs over 120,000 people in its two divisions, Pharmaceutical and MedTech. It spun off its consumer healthcare division in 2023, naming it Kenvue. About 64% of its $88.8 billion in 2024 revenues came from its pharmaceutical division, while the remaining 36% was from its MedTech operations.
Wealth Builder
Sorry!
Only current subscribers of the Internet Wealth Builder may view the details of this recommendation.
Income Investor
JNJ stock is more than 15% below its record high of 2022, leaving it at a mid-teens p/e multiple. It trades at a 40% discount to the broader market. Revenue and adjusted earnings continue to grow in the mid to high single digit percentages. The stock remains a Buy. - Gavin Graham
Sorry!
Only current subscribers of The Income Investor may view the details of this recommendation.
Interactive Performance Chart
JNJ was first recommended here on October 27, 2010